These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Suramin and serum insulin-like growth factor levels in metastatic cancer patients.
    Author: Miglietta L, Barreca A, Repetto L, Costantini M, Rosso R, Boccardo F.
    Journal: Anticancer Res; 1993; 13(6B):2473-6. PubMed ID: 8135485.
    Abstract:
    Suramin, a polysulphonated naphthylurea, inhibits the activity of several growth factors in in vitro experiments and clinical responses have been reported in human solid tumors. We decided to investigate the relationship between suramin treatment and serum levels of insulin-like growth factor I (IGF-I) and II (IGF-II) in advanced breast, prostate and lung cancer patients. The serum IGF-I, IGF-II levels were determined by radioimmunoassay. A significant decline of IGF-I and IGF-II serum levels was demonstrated in suramin treated patients. Our results suggest that suramin-induced IGF suppression could be one of the possible mechanisms of suramin action.
    [Abstract] [Full Text] [Related] [New Search]